MISE

ValGenesis and LifeBee Announce Strategic Partnership to Address Digital Validation Needs of Life Science Companies Across Europe

Retrieved on: 
Monday, November 28, 2022
SAN, PDA, Title 21 CFR Part 11, Laboratory, Lead, Parenteral Drug Association, Multimedia, Partner, Partnership, MISE, Regulation, GMP, U.S. FDA, Fourth Industrial Revolution, Pharmacovigilance, Medical device, Risk management, Online shopping, Fine chemical, GxP

ValGenesis is the market leader in enterprise Validation Lifecycle Management Systems (VLMS), helping the world's leading life sciences companies enforce compliance and enable standardization with 100% digital, risk-based validation software.

Key Points: 
  • ValGenesis is the market leader in enterprise Validation Lifecycle Management Systems (VLMS), helping the world's leading life sciences companies enforce compliance and enable standardization with 100% digital, risk-based validation software.
  • In this partnership, LifeBee will implement and manage next-generation digital validation tools developed by ValGenesis, enabling clients to further strengthen risk and compliance across the GMP lifecycle.
  • LifeBee | Digitalizing Life Sciences is a business and digital consulting boutique firm supporting life science companies on their path toward digitalization, operational excellence and compliance with customized advisory and innovative digital solutions.
  • ValGenesis, Inc. is the creator of an innovative software platform that serves as a foundation for managing compliance-based validation activities in life science companies.

ValGenesis and Xevalics Consulting Partner to Deliver Best-in-Class Computer Software Assurance and Risk Management Solutions for Life Sciences Companies Across the U.S.

Retrieved on: 
Tuesday, September 13, 2022
U.S. FDA, Risk, FDA, PDA, CSA, Industry, Compliance, CSV, Information technology, Parenteral Drug Association, Partnership, Fourth Industrial Revolution, Technology, Title 21 CFR Part 11, Risk management, Solution, Cloud computing, SAN, GMP, MISE, Medical device

Xevalics is a consulting company specializing in computer software assurance (CSA), computer system validation (CSV), and risk management.

Key Points: 
  • Xevalics is a consulting company specializing in computer software assurance (CSA), computer system validation (CSV), and risk management.
  • In this partnership, Xevalics will implement and manage next-generation digital validation tools developed by ValGenesis, enabling clients to further strengthen CSA and risk and compliance across the GMP lifecycle.
  • With ValGenesis technology, Xevalics will serve a wider network of life sciences companies across the U.S. and the globe.
  • ValGenesis, Inc. is the creator of an innovative software platform that serves as a foundation for managing compliance-based validation activities in life science companies.

Ferrari Signs Memorandum of Understanding With Mise, Invitalia and the Emilia-Romagna Region.

Retrieved on: 
Tuesday, March 22, 2022
Maranello, MISE, Banca Intesa, DNA, Investment, National Agency for Science and Engineering Infrastructure, Economic development, NYSE, Ferrari, Research, Capital market, Employment, Technology, Memorandum, Education, Contratto, Renewable energy

Maranello22 March 2022 Ferrari N.V. (NYSE/EXM: RACE) (Ferrari or the Company) today signed a Memorandum of Understanding (Protocollo di Intesa) with the Italian Ministry of Economic Development (MISE), Invitalia (the National Agency for Inward Investment and Economic Development S.p.A.) and the Emilia-Romagna Region.

Key Points: 
  • Maranello22 March 2022 Ferrari N.V. (NYSE/EXM: RACE) (Ferrari or the Company) today signed a Memorandum of Understanding (Protocollo di Intesa) with the Italian Ministry of Economic Development (MISE), Invitalia (the National Agency for Inward Investment and Economic Development S.p.A.) and the Emilia-Romagna Region.
  • According to the Memorandum of Understanding, the Institutions involved will support Ferraris plan, which involves investments in technology and production, with a strong focus on innovation as well as a social and environmental commitment.
  • The plan will significantly benefit the territory of Maranello and Modena, and will lead to the employment of 250 new hires.
  • Ferrari will present its industrial plan at the Capital Markets Day, scheduled for 16 June 2022.

Modis and ValGenesis Partner to Bring Best-in-Class Digital Commissioning & Qualification Validation Processes to the Italian Pharmaceutical Industry

Retrieved on: 
Thursday, February 17, 2022
Cloud, List of life sciences, Cloud Infrastructure Management Interface, PDA, Communication, CEO, The Adecco Group, Parenteral Drug Association, MISE, Title 21 CFR Part 11, Automotive industry, SAN, High Tech Academy, Consultant, Fourth Industrial Revolution, Goal, Health care, Compliance, Industrial, Cognitive Technologies, Partnership, Digital transformation, Risk management, U.S. FDA, Internet Communications Engine, Engineering, Financial services, Biophysical environment, Industry, Transport, Fine chemical, Cryptocurrency, Software, Modis

ValGenesis is the industry innovator of paperless validation, and the inventor of ValGenesis VLMS, the industry's first, proven, 100% paperless validation lifecycle management solution.

Key Points: 
  • ValGenesis is the industry innovator of paperless validation, and the inventor of ValGenesis VLMS, the industry's first, proven, 100% paperless validation lifecycle management solution.
  • By combining Modis' expertise with ValGenesis' validation lifecycle management solutions, pharma companies can implement their digitization plans in accordance with the guidelines of Industry 4.0 and MISE.
  • Through ValGenesis VLMS, Modis can deliver new levels of digital collaboration, data integrity, risk management and compliance with validation lifecycle processes to help pharma companies bring their products to market faster.
  • We are thrilled to partner with Modis and aggressively pursue our vision of empowering even more companies to achieve their digital validation goals," he stated.